NCT04052204 - Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 30, 2019

Primary Completion Date

September 29, 2020

Study Completion Date

September 29, 2020

Conditions

Squamous Cell Carcinoma of the Head and Neck (SCCHN)Metastatic Castration Resistant Prostate Cancer (mCRPC)

Interventions

DRUG

avelumab

Investigational fully human anti-PD-L1 monoclonal antibody

DRUG

Bempegaldesleukin

Investigational CD122-biased cytokine agonist

DRUG

talazoparib

poly (adenosine diphosphate \[ADP\] ribose) polymerase (PARP) inhibitor

DRUG

enzalutamide

androgen receptor inhibitor

Trial Locations (5)

GZA Ziekenhuizen campus Sint-Augustinus, Wilrijk

University of Rochester Medical Center, Rochester

Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy, Warsaw

Hospital Quirón Barceloma, Barcelona

Hospital Universitari Vall d'Hebron, Barcelona